KR20050057525A - 피부 건강을 평가하기 위한 키트 및 방법 - Google Patents
피부 건강을 평가하기 위한 키트 및 방법 Download PDFInfo
- Publication number
- KR20050057525A KR20050057525A KR1020057004865A KR20057004865A KR20050057525A KR 20050057525 A KR20050057525 A KR 20050057525A KR 1020057004865 A KR1020057004865 A KR 1020057004865A KR 20057004865 A KR20057004865 A KR 20057004865A KR 20050057525 A KR20050057525 A KR 20050057525A
- Authority
- KR
- South Korea
- Prior art keywords
- polymorphism
- disease
- encoding
- residue
- gene encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 115
- 230000036541 health Effects 0.000 title claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 356
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 282
- 201000010099 disease Diseases 0.000 claims abstract description 276
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 120
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 120
- 230000036559 skin health Effects 0.000 claims abstract description 91
- 208000017520 skin disease Diseases 0.000 claims abstract description 70
- 230000035945 sensitivity Effects 0.000 claims abstract description 15
- 239000002773 nucleotide Substances 0.000 claims abstract description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 60
- 108091034117 Oligonucleotide Proteins 0.000 claims description 54
- 108020004705 Codon Proteins 0.000 claims description 48
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 38
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 37
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 37
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 35
- 101710112368 Glutathione S-transferase P 1 Proteins 0.000 claims description 31
- 108020002908 Epoxide hydrolase Proteins 0.000 claims description 29
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 29
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 29
- 108700026244 Open Reading Frames Proteins 0.000 claims description 29
- 230000008859 change Effects 0.000 claims description 29
- 102000005486 Epoxide hydrolase Human genes 0.000 claims description 28
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 26
- 230000001086 cytosolic effect Effects 0.000 claims description 25
- 108010053835 Catalase Proteins 0.000 claims description 24
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 22
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 claims description 22
- 230000002438 mitochondrial effect Effects 0.000 claims description 22
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 21
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 21
- 108091026890 Coding region Proteins 0.000 claims description 20
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 19
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims description 18
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 18
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 16
- 235000016709 nutrition Nutrition 0.000 claims description 16
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 15
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 108020005029 5' Flanking Region Proteins 0.000 claims description 14
- 102000016938 Catalase Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 108010002998 NADPH Oxidases Proteins 0.000 claims description 13
- 102000004722 NADPH Oxidases Human genes 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 12
- 108010007843 NADH oxidase Proteins 0.000 claims description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 12
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 12
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 12
- 239000004474 valine Substances 0.000 claims description 12
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
- 101150008380 gstp1 gene Proteins 0.000 claims description 8
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 8
- 229960000310 isoleucine Drugs 0.000 claims description 8
- 229940113082 thymine Drugs 0.000 claims description 8
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 6
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 239000004593 Epoxy Substances 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 102000004157 Hydrolases Human genes 0.000 claims description 4
- 108090000604 Hydrolases Proteins 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 4
- 210000003470 mitochondria Anatomy 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 20
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 13
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 241000282412 Homo Species 0.000 abstract description 22
- 238000011156 evaluation Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 50
- 239000000047 product Substances 0.000 description 26
- 239000000523 sample Substances 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 239000001301 oxygen Substances 0.000 description 17
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 16
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 16
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 15
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 102000003849 Cytochrome P450 Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 8
- 238000000137 annealing Methods 0.000 description 7
- 239000011814 protection agent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010071602 Genetic polymorphism Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000033616 DNA repair Effects 0.000 description 4
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 231100001231 less toxic Toxicity 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 230000037075 skin appearance Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000212314 Foeniculum Species 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- -1 hydroxy radicals Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000003009 skin protective agent Substances 0.000 description 3
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000015724 Trifolium pratense Nutrition 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 235000013526 red clover Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000156753 Calycophyllum candidissimum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022535 Infectious Skin disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 241001267511 Pikea Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010052891 Skin bacterial infection Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 1
- WJZHMLNIAZSFDO-UHFFFAOYSA-N manganese zinc Chemical compound [Mn].[Zn] WJZHMLNIAZSFDO-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/247,935 | 2002-09-20 | ||
| US10/247,935 US7211383B2 (en) | 2001-04-05 | 2002-09-20 | Kits and methods for assessing skin health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050057525A true KR20050057525A (ko) | 2005-06-16 |
Family
ID=32028981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057004865A Ceased KR20050057525A (ko) | 2002-09-20 | 2003-09-19 | 피부 건강을 평가하기 위한 키트 및 방법 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7211383B2 (enExample) |
| EP (1) | EP1581094A4 (enExample) |
| JP (3) | JP2006513699A (enExample) |
| KR (1) | KR20050057525A (enExample) |
| AU (1) | AU2003275038B2 (enExample) |
| CA (1) | CA2499390C (enExample) |
| WO (1) | WO2004026107A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101109043B1 (ko) * | 2008-12-30 | 2012-02-09 | 사회복지법인 삼성생명공익재단 | 각질세포 또는 혈청 유래의 아토피성 피부질환 마커 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7054758B2 (en) * | 2001-01-30 | 2006-05-30 | Sciona Limited | Computer-assisted means for assessing lifestyle risk factors |
| US20020146698A1 (en) * | 2001-04-05 | 2002-10-10 | Genelink, Inc. | Kits and methods for assessing oxidative stress |
| US7211383B2 (en) * | 2001-04-05 | 2007-05-01 | Genelink, Inc. | Kits and methods for assessing skin health |
| FI20040227L (fi) * | 2004-02-13 | 2005-08-14 | Jurilab Ltd Oy | Menetelmä syövän, sepelvaltimotaudin ja aivohalvauksen riskin havaitsemiseksi |
| CN100412208C (zh) * | 2006-04-07 | 2008-08-20 | 甄二真 | 基于基因多态性的皮肤美容保健方法 |
| WO2009127073A1 (de) * | 2008-04-18 | 2009-10-22 | Gen Sod2 Foundation | Auf ein individuum abgestimmte kosmetikzubereitung und verfahren zu deren herstellung |
| US20100304373A1 (en) * | 2008-08-14 | 2010-12-02 | Ricciardi Robert P | Methods for Assessing the Susceptibility of a Human to Diminished Health and Wellness |
| JP2011115098A (ja) * | 2009-12-04 | 2011-06-16 | Nippon Menaade Keshohin Kk | 加齢による皮膚明度の低下を予測する皮膚評価方法 |
| GB2493141A (en) * | 2011-07-19 | 2013-01-30 | Gene Onyx Ltd | Method of selecting a product using a DNA sample |
| KR101803980B1 (ko) * | 2011-08-03 | 2017-12-04 | 주식회사 엘지생활건강 | 민감성 피부 타입 유전자 다형성 마커 및 이의 용도 |
| GB2497766A (en) * | 2011-12-20 | 2013-06-26 | Gene Onyx Ltd | Snp analysis to determine efficacy of skin care product |
| KR20160075501A (ko) * | 2013-09-25 | 2016-06-29 | 더 프록터 앤드 갬블 캄파니 | 피부 케어 상담을 위한 방법 및 시스템 |
| JP6328903B2 (ja) * | 2013-10-10 | 2018-05-23 | ジェネシスヘルスケア株式会社 | 皮膚関連遺伝子に基づく肌におけるリスク判別システム |
| CN108048423B (zh) * | 2018-01-15 | 2020-05-08 | 江南大学 | 一种催化活性提高的菜豆环氧化物水解酶突变体及其应用 |
| KR102346186B1 (ko) * | 2019-12-23 | 2022-01-03 | 주식회사 테라젠바이오 | 피부 민감 위험도 예측용 바이오마커 및 이의 용도 |
| KR20220137382A (ko) * | 2021-04-02 | 2022-10-12 | 주식회사 엘지생활건강 | 주름 피부 타입 판단용 유전자 다형성 마커 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3616923A1 (de) | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
| US6013431A (en) | 1990-02-16 | 2000-01-11 | Molecular Tool, Inc. | Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| CA2139667C (en) | 1992-07-06 | 2005-03-29 | Spencer B. Farr | Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes |
| US5643623A (en) | 1995-06-07 | 1997-07-01 | Mars Incorporated | Health food product and its uses |
| US6291171B1 (en) | 1995-11-15 | 2001-09-18 | Robert P. Ricciardi | Kit for the non-invasive identification and collection of DNA |
| US5891622A (en) | 1996-09-30 | 1999-04-06 | Oxford Biomedical Research, Inc. | Assessment of oxidative stress in vivo |
| US5955111A (en) | 1996-10-08 | 1999-09-21 | Hartford Hospital | Methods and compositions for inducing production of stress proteins |
| US5920634A (en) * | 1996-11-13 | 1999-07-06 | Chiquette; Grace Rojan | Activatable audio advertising display standard |
| JP3381053B2 (ja) | 1996-11-29 | 2003-02-24 | 日研フード株式会社 | 酸化的ストレス判断解析表 |
| US6133039A (en) | 1998-02-09 | 2000-10-17 | Washinton University | In vivo method for determination of oxidative stress |
| US20020146698A1 (en) | 2001-04-05 | 2002-10-10 | Genelink, Inc. | Kits and methods for assessing oxidative stress |
| EP1386001A4 (en) * | 2001-04-05 | 2005-07-20 | Genelink Inc | KITS AND METHOD FOR ASSESSING OXIDATIVE STRESS |
| US7211383B2 (en) | 2001-04-05 | 2007-05-01 | Genelink, Inc. | Kits and methods for assessing skin health |
-
2002
- 2002-09-20 US US10/247,935 patent/US7211383B2/en not_active Expired - Lifetime
-
2003
- 2003-09-19 CA CA2499390A patent/CA2499390C/en not_active Expired - Fee Related
- 2003-09-19 KR KR1020057004865A patent/KR20050057525A/ko not_active Ceased
- 2003-09-19 AU AU2003275038A patent/AU2003275038B2/en not_active Ceased
- 2003-09-19 WO PCT/US2003/029529 patent/WO2004026107A2/en not_active Ceased
- 2003-09-19 JP JP2004538253A patent/JP2006513699A/ja not_active Withdrawn
- 2003-09-19 EP EP03759308A patent/EP1581094A4/en not_active Withdrawn
-
2007
- 2007-03-30 US US11/731,180 patent/US8313930B2/en not_active Expired - Fee Related
-
2010
- 2010-07-08 JP JP2010155397A patent/JP2010263906A/ja active Pending
-
2012
- 2012-11-05 US US13/668,842 patent/US20130130247A1/en not_active Abandoned
-
2013
- 2013-08-05 JP JP2013161944A patent/JP2013240351A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101109043B1 (ko) * | 2008-12-30 | 2012-02-09 | 사회복지법인 삼성생명공익재단 | 각질세포 또는 혈청 유래의 아토피성 피부질환 마커 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006513699A (ja) | 2006-04-27 |
| US20130130247A1 (en) | 2013-05-23 |
| EP1581094A4 (en) | 2008-04-23 |
| EP1581094A2 (en) | 2005-10-05 |
| US7211383B2 (en) | 2007-05-01 |
| WO2004026107A3 (en) | 2005-12-22 |
| AU2003275038B2 (en) | 2009-09-03 |
| WO2004026107A2 (en) | 2004-04-01 |
| CA2499390A1 (en) | 2004-04-01 |
| JP2010263906A (ja) | 2010-11-25 |
| CA2499390C (en) | 2013-08-20 |
| US8313930B2 (en) | 2012-11-20 |
| US20070178518A1 (en) | 2007-08-02 |
| JP2013240351A (ja) | 2013-12-05 |
| US20030073612A1 (en) | 2003-04-17 |
| AU2003275038A1 (en) | 2004-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8313930B2 (en) | Kits and methods for assessing skin health | |
| Hayden et al. | Molecular genetics of bipolar disorder | |
| Turkcu et al. | The association of FOXO3A gene polymorphisms with serum FOXO3A levels and oxidative stress markers in vitiligo patients | |
| Thompson et al. | Serotonin transporter gene polymorphisms in alcohol dependence | |
| JP2010263906A5 (enExample) | ||
| Parıldar-Karpuzoğlu et al. | Single nucleotide polymorphisms in base-excision repair genes hOGG1, APE1 and XRCC1 do not alter risk of Alzheimer's disease | |
| Dong et al. | SOD3 and eNOS genotypes are associated with SOD activity and NOx | |
| US20130011838A1 (en) | Kits And Methods For Assessing Oxidative Stress | |
| Hashimoto et al. | The breakpoint cluster region gene on chromosome 22q11 is associated with bipolar disorder | |
| Salgueiro et al. | Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients | |
| Nagy et al. | Schöpf-Schulz-Passarge syndrome resulting from a homozygous nonsense mutation in WNT10A | |
| Carneiro et al. | Disruption of alternative NAD (P) H dehydrogenases leads to decreased mitochondrial ROS in Neurospora crassa | |
| AU2002309543B2 (en) | Kits and methods for assessing oxidative stress | |
| AU2002309543A1 (en) | Kits and methods for assessing oxidative stress | |
| JP2009511026A (ja) | 血栓塞栓性及び冠状動脈性心疾患の診断方法 | |
| JP2006191858A (ja) | シミ、ソバカスまたは茶黒髪の予測方法並びにそれに基づく化粧品の選択方法 | |
| Smith et al. | Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralen–ultraviolet A photochemotherapy | |
| Abdel Rasol et al. | The effect of catalase enzyme gene polymorphism A-21T (rs7943316) on epilepsy and its drug resistance after hypoxic ischemic brain injury | |
| Martin et al. | Manganese superoxide dismutase gene coding region polymorphisms lack clinical incidence in general population | |
| Mitrofanov et al. | Frequency of the 735G→ A mutation of the 5′-splice donor site of intron 14 of the dihydropyrimidine dehydrogenase gene (DPYD) in residents of novosibirsk region (Russia) as revealed with fluorescent oligonucleotides | |
| Hong et al. | Differentially Expressed Genes by Inhibition of C-terminal Src Kinase by siRNA in Human Vascular Smooth Muscle Cells and Their Association with Blood Pressure | |
| Nene-Bi et al. | L-004 DIURETIC ACTIVITY OF THE AQUEOUS EXTRACT OF BRIDELIA FERRUGINEA BENTH.(EUPHORBIACEAE) INNORMAL RATS | |
| Amorim et al. | Endothelial Nitric Oxide Synthase Gene Polymorphism and Periodontal Disease | |
| TenNapel | Oxidative stress genes and gender-specific analysis of lifespan, blood pressure, and incident stroke in the Iowa 65+ cohort | |
| Wu et al. | Three single-nucleotide polymorphisms of the angiotensinogen gene and |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050321 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20080919 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20101111 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20110825 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20101111 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |